WAYNE, PA – July 22, 2025. Emperion shared today the completion of the PeerLink acquisition, previously announced July 9, 2025. The successful close of this transaction marks a significant milestone in advancing Emperion’s position in the workers’ compensation, auto, disability and healthcare markets and enhances its ability to deliver all levels of peer review.

WAYNE, PA – July 9, 2025. Emperion, a leader in outsourced clinical review services, announced it has signed an agreement to acquire PeerLink, an independent peer review services company, based in Birmingham, Alabama. The acquisition strengthens Emperion’s position in the workers’ compensation, auto, disability and healthcare markets and enhances its ability to deliver all levels of peer review.

WAYNE, PA – January 21, 2025. Emperion is pleased to announce that Drew Murphy has joined the company as its new Senior Vice President and Chief Financial Officer (CFO). With a proven track record of financial leadership and strategic guidance, Murphy will play a key role in driving Emperion’s growth and development.

WAYNE, PA – April 25, 2024. Emperion is proud to announce the appointment of Matt Padden as the newest addition to its leadership team. With a proven track record of driving sales growth and cultivating strong client relationships, Padden brings a wealth of experience and expertise to the Emperion team.

WAYNE, PA – April 3, 2024. Emperion and Enlyte leaders have completed the separation of IME, Peer Review (PR), and Independent Review Organization (IRO) services from Enlyte to Emperion, following the agreement announced in February. Emperion will focus on expanded product development and investment opportunities for these and related solutions.

SAN DIEGO, CA - March 5, 2024. Enlyte and its Board of Directors have made the strategic decision to transfer its Independent Medical Examination (IME) business and more than 350 employees from Enlyte to the creation of a new, stand-alone IME company, Emperion, Inc. Emperion will be owned by Stone Point Capital, Enlyte’s current shareholder, through its Trident Funds and a management team led by former Genex executives.